Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

 

Press Releases
Nov 15, 2017

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the...

Nov 9, 2017

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data on AGEN1884 (CTLA-4) and AGEN2034 (PD-1)...

Nov 8, 2017

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and...

VIEW ALL PRESS RELEASES

Stock Chart
NASDAQAGEN
Events and Presentations
Wednesday, November 15, 2017
8:00am GMT
Tuesday, November 7, 2017
11:00am - 12:00pm EST
Tuesday, September 26, 2017
1:00pm - 1:25pm EDT

“the